European Oncology and Haematology最新文献_第3页

A Patient Presenting with Severe Hypoglycaemia and Autonomic Instability Found to Have Multiple Myeloma Complicated with Amyloidosis 一例以严重低血糖和自主神经不稳定为表现的多发性骨髓瘤合并淀粉样变患者

European Oncology and Haematology Pub Date : 2019-01-01 DOI: 10.17925/eoh.2019.15.2.106

K. Jayawickreme, S. Subasinghe, Rochana De Silva, P. Dissanayake, L. Perera

引用次数: 0

Finding and treating gaucher disease type 1 - The role of the haematologist 戈谢病1型的发现和治疗——血液病学家的作用

European Oncology and Haematology Pub Date : 2018-06-01 DOI: 10.17925/EOH.2018.14.1.50

M. Cappellini, E. Cassinerio, I. Motta, W. Morello, J. Villarubia

{"title":"Finding and treating gaucher disease type 1 - The role of the haematologist","authors":"M. Cappellini, E. Cassinerio, I. Motta, W. Morello, J. Villarubia","doi":"10.17925/EOH.2018.14.1.50","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.50","url":null,"abstract":"Gaucher disease (GD) type 1 is the most common lysosomal storage disease and the most common genetic disorder among Ashkenazi Jews. The majority of patients with GD present with unexplained splenomegaly and/or thrombocytopenia, and the disorder often affects children; consequently, haematologists and paediatricians are ideally placed to diagnose this condition. Prompt management of GD type 1 using enzyme-replacement therapy or substrate reduction therapy can reduce the risk of developing long-term GD complications and reverse many of the initial signs/symptoms, thereby improving both quality and duration of life. Treatment is most effective when initiated early; consequently, a prompt diagnosis is essential. Despite this, the average time to diagnosis following the onset of clinical symptoms is 4 years. Reasons for the delay include the heterogeneous nature of the disease, together with a lack of awareness of rare haematological disorders and the benefits of early treatment. Indeed, studies show that only 20% of haematologists consider GD type 1 in their differential diagnosis for patients presenting with splenomegaly and/or thrombocytopenia. To help raise awareness of GD, reduce the diagnostic delay and prevent unnecessary tissue biopsies, simple diagnostic algorithms and screening tools have been developed and validated, both in adults and in children.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89103225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Belarus Experience of Pelvic Artery Embolisation in Patients with Advanced and Recurrent Cervical Cancer Presenting with Haemorrhage 盆腔动脉栓塞治疗晚期和复发宫颈癌出血的白俄罗斯经验

European Oncology and Haematology Pub Date : 2018-06-01 DOI: 10.17925/EOH.2018.14.1.45

O. P. Matylevich, V. Akinfeev, T. Randall, K. Schmeler, O. Sukonko

引用次数: 3

The Impact of Biosimilars in Supportive Care in Cancer 生物仿制药对癌症支持治疗的影响

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.20

P. Cornes, M. Aapro

引用次数: 7

BRAF-mutant Melanoma – The COLUMBUS Trial braf突变黑色素瘤-哥伦布试验

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.78

R. Dummer

引用次数: 0

Shaping Macrophage Plasticity with Iron – Towards a New Therapeutic Approach 铁塑造巨噬细胞的可塑性——一种新的治疗方法

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.76

F. Vinchi

引用次数: 0

Proton Beam Therapy 质子束治疗

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.82

Jason Lester

引用次数: 0

New Approaches to Multiple Myeloma 多发性骨髓瘤的新方法

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.18

I. Ghobrial

{"title":"New Approaches to Multiple Myeloma","authors":"I. Ghobrial","doi":"10.17925/EOH.2018.14.1.18","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.18","url":null,"abstract":"Support: No funding was received in the publication of this article. Over recent years, there have been significant advances in the treatment of multiple myeloma, including the introduction of novel drugs, which have changed the entire treatment paradigm. The rapid pace of developments in this field have led to the initiation of the annual International Congress on Controversies in Multiple Myeloma (COMy) which began in 2014. The 4th congress was held in Paris on 3–5 May 2018. A highlight of the congress is the Multiple Myeloma Excellence Award, in recognition of innovative research and clinical work that has contributed significantly to progress in the field of multiple myeloma and plasma cell dyscrasias. This year, Irene Ghobrial of the Michele & Stephen Kirsch Laboratory, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, US, was a recipient of the award. In addition to her established research portfolio in the field of multiple myeloma, it has recently been announced that Dr Ghobrial is to lead a Stand Up To Cancer Multiple Myeloma Dream Team project, which is the first large-scale population survey in the USA for precursor conditions of multiple myeloma. In an expert interview, Dr Ghobrial discusses the award, the latest advances in multiple myeloma research and the Stand Up To Cancer project.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91124463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lenvatinib in Hepatocellular Carcinoma Lenvatinib在肝细胞癌中的应用

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.80

M. Marcao, Hertfordshire Uk Vice President Oncology at Eisai Emea

引用次数: 0

Centrifugal and Membrane Therapeutic Plasma Exchange – A Mini-review 离心和膜治疗血浆交换-一个小回顾

European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.105

M. Janssens, S. Wakelin, Zaventum Belgium Terumo Bct Europe Nv, Goring-on-Thames Uk Touch Medical Media

{"title":"Centrifugal and Membrane Therapeutic Plasma Exchange – A Mini-review","authors":"M. Janssens, S. Wakelin, Zaventum Belgium Terumo Bct Europe Nv, Goring-on-Thames Uk Touch Medical Media","doi":"10.17925/EOH.2018.14.2.105","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.2.105","url":null,"abstract":"During therapeutic plasma exchange (TPE), a large volume of a patient’s plasma is separated from the cellular components of the blood and replaced with appropriate fluids to remove circulating plasma components and disease mediators such as antibodies, cholesterol, toxins and drugs. Automated TPE systems can be categorised into two distinct groups based on the method of plasma separation: centrifugal TPE (cTPE) and membrane filtration TPE (mTPE). While technical and performance parameters for various TPE systems have been reported previously, the recent publication of several head-to-head studies directly comparing the Spectra Optia cTPE system (Terumo BCT, Lakewood, CO, US) with mTPE systems has increased the understanding of their performance. This review summarises the comparative information between the systems. Although both device types are well tolerated, the majority of technical variables favour the cTPE system over mTPE systems, with a low risk of clotting events and benefits in plasma removal efficiency and hence procedure time. Platelet loss with the cTPE system was also shown to be similar or reduced compared with mTPE systems. Finally, flow rate requirements limit the use of peripheral venous access with mTPE devices, but not cTPE devices. Conclusively, several important differences exist between cTPE and mTPE systems that may influence treatment decisions.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"7 1","pages":"105"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75186141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8